Bank of New York Mellon’s Starling Oncology, Inc. Common Stock STLN Stock Holding History
Bought
Maintained
Sold
Other funds holding STLN
MLM
KWA
GCP
WPC
TC
Bank of New York Mellon's STLN Position: Q2 2026 in Review
Bank of New York Mellon increased its Starling Oncology, Inc. Common Stock (STLN) stake by 8.9% in Q2 2026, buying an estimated $60.9K and bringing the position to 176,949 shares worth $961K. The position accounts for ﹤0.01% of the portfolio, ranked #3384.
Bank of New York Mellon first reported a position in STLN in Q2 2022 and has held it in 15 quarters since. 41 funds tracked by Wall St. Rank hold STLN as of Q2 2026.
- Bank of New York Mellon held 176,949 shares of Starling Oncology, Inc. Common Stock worth $961K as of Q2 2026.
- Bank of New York Mellon bought 14,507 Starling Oncology, Inc. Common Stock shares in Q2 2026, an estimated $60.9K.
- Starling Oncology, Inc. Common Stock made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3384 holding.
- Bank of New York Mellon first reported a position in Starling Oncology, Inc. Common Stock in Q2 2022 and has held it in 15 quarters since.
- 41 funds tracked by Wall St. Rank held Starling Oncology, Inc. Common Stock as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.